May 6, 2021

Dermavant Announces Appointment of
Michael Swartzburg as Chief Financial Officer

- Over 20 Years of Combined Experience in Global Finance Leadership, Audit, and Advisory Roles in the Biopharmaceutical Industry Read Press Release
Feb 18, 2021

Positive Data from PSOARING 3 Support
Long-Term Use of Tapinarof Cream in Adults with Plaque Psoriasis, with Durable (On-Therapy) and Remittive (Off-Therapy) Benefits

Read Press Release
FORTUNE Names Dermavant One of the 2021 Best Workplaces in Health Care & Biopharma™

©2021 FORTUNE Media IP Limited. All rights reserved. Used under license.
Read Press Release
Dermavant Named One of Fortune® Magazine’s 2020 “100 Best Small and Medium Companies to Work For”

©2020 FORTUNE Media IP Limited. All rights reserved. Used under license.
Read Press Release
Dermavant Voices:

Patient‑Focused Innovation

Watch Dermavant Chief Medical Officer Philip Brown, MD, JD, share his passion for helping people.
Watch the Video
Dermavant’s

Robust Pipeline

Dermavant’s medical dermatology pipeline includes product candidates that target specific unmet needs in two of the largest growing immuno-dermatology markets, psoriasis and atopic dermatitis, as well as other large markets, including vitiligo, primary focal hyperhidrosis, and acne.
See More

A Passion for Science and a Commitment to Dermatology

Dermavant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage biopharmaceutical company committed to fostering unprecedented change and unparalleled impact in immuno-dermatology. We’re doing this by thinking differently, pushing the boundaries of science and partnering with providers in new ways—all with one goal: transforming the lives of millions of patients with skin diseases.

Dermavant Voices: Patient-Focused Innovation

“The ability to transform lives”

Todd Zavodnick
Chief Executive Officer

“A passion for helping people”

Philip M Brown, MD, JD
Chief Medical Officer

“Fundamentally changing the lives of patients”

David Rubenstein, MD, PhD
Chief Scientific Officer

DERMAVANT. Innovating. Pioneering. Transforming.

We Will Transform Dermatology.

VIEW CORPORATE FACT SHEET

Latest News

May 6, 2021

Dermavant Announces Appointment of Michael Swartzb ...

April 16, 2021

Dermavant Announces Tapinarof Data Presentations a ...

March 25, 2021

FORTUNE Names Dermavant One of the 2021 Best Workp ...

Dermavant Announces Appointment of Michael Swartzburg as Chief Financial Officer

Positive Data from PSOARING 3 Support Long-Term Use of Tapinarof Cream in Adults with Plaque Psoriasis, with Durable (On-Therapy) and Remittive (Off-Therapy) Benefits

FORTUNE Names Dermavant One of the 2021 Best Workplaces in Health Care & Biopharma™

Dermavant Named One of Fortune® Magazine’s 2020 “100 Best Small and Medium Companies to Work For”

Dermavant Voices:

Patient‑Focused Innovation

Dermavant’s

Robust Pipeline